MaaT Pharma SA (EPA:MAAT)
France · Delayed Price · Currency is EUR 2.930
+0.075 (2.63%)
Jun 3, 2026, 5:35 PM CET
MaaT Pharma Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, MaaT Pharma stock has a consensus rating of "Buy" and an average price target of €10.00. The average 1-year stock price forecast is 241.30% higher than the current stock price, while the lowest is €3.00 (+2.39%) and the highest is €17.00 (+480.20%).
Price Target: €10.00 (+241.30%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 31, 2026.
Analyst Ratings
The average analyst rating for MaaT Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains €19.00 | Buy | Maintains | €19.00 | +548.46% | Mar 31, 2026 |
| Kepler Capital | Kepler Capital | Buy Maintains €17.00 | Buy | Maintains | €17.00 | +480.20% | Mar 31, 2026 |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. The data is sourced from Wall Street analysts. Data sources.